Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsia

Pooneh Nikuei,Minoo Rajaei,Nasibeh Roozbeh,Fatemeh Mohseni,Fatemeh Poordarvishi,Mohsen Azad,Solmaz Haidari

doi:10.1186/s12884-020-2744-2

Pooneh Nikuei, Minoo Rajaei + Show 5 more

Open Access

https://doi.org/10.1186/s12884-020-2744-2

Copy DOI

Abstract

BackgroundPreeclampsia (PE) is a serious complication of pregnancy and one of the main causes of maternal and neonatal mortality and morbidity in the world. Finding a biomarker with high sensitivity and specificity could lead to prediction and early diagnosis of the disease and reduces its complications. In this study, we evaluated diagnostic accuracy of Soluble fms-like tyrosine kinase-1 (sFlt-1) to Placental growth factor (PlGF) ratio for diagnosis of PE.MethodsThe cases included 23 mild, 15 severe preeclamptic patients, and 20 normal term pregnant women as control referred to GYN ward of the Persian Gulf Hospital in Bandar Abbas from 2014 to 2016. Levels of sFlt-1 and PlGF were measured. Receiver Operating Characteristic (ROC) curve analysis was applied to calculate diagnostic accuracy of sFlt-1/PlGF ratio.ResultsThe mean Level of sFlt-1/PlGF in PE patients (91.33 ng/ml) was significantly higher than control women (17.62) (P<0.001). ROC curve analysis showed sFlt-1/PlGF ratio diagnostic accuracy in preeclamptic patients with Area Under Curve (AUC) of 0.90, the best cut-off value of 24.96, sensitivity and specificity of 84.2 and 85.0%, respectively.ConclusionsOur data showed sFlt-1/PlGF ratio has higher accuracy for differentiating PE patients from non-PEs in comparison with its power for differentiating severe or early onset forms of the disease.

Highlights

Preeclampsia (PE) is a serious complication of pregnancy and one of the main causes of maternal and neonatal mortality and morbidity in the world
Severe and controls the mean level of Soluble fms-like tyrosine kinase-1 (sFlt-1)/Placental growth factor (PlGF) was 130.97 in severe PE patients which was significantly increased compared to controls (P
The level of sFlt-1/PlGF was higher in severe PE patients compared to mild women, there was no significant difference between these two groups (P = 0.389)

Summary

Introduction

Preeclampsia (PE) is a serious complication of pregnancy and one of the main causes of maternal and neonatal mortality and morbidity in the world. Finding a biomarker with high sensitivity and specificity could lead to prediction and early diagnosis of the disease and reduces its complications. Preeclampsia (PE) is diagnosed after 20 weeks of gestation [1]. This multisystem disorder affects 2–7% of pregnant women [2]. PE is one of the major causes of maternal death, neonatal mortality and premature deliveries [3, 4]. Early-onset PE develops before 34 weeks of gestation, while late-onset PE develops at or after 34 weeks of gestation.

Objectives

Methods

Results

Conclusion